- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.09. | RespireRx Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.08. | RespireRx Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | RespireRx Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.03. | RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury | 134 | GlobeNewswire (Europe) | Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx"or the"Company"), focused on the discovery and development of innovative and... ► Artikel lesen | |
| 13.02. | RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine | 269 | GlobeNewswire (Europe) | Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and... ► Artikel lesen | |
| RESPIRERX Aktie jetzt für 0€ handeln | |||||
| 04.01. | RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient | 239 | GlobeNewswire (Europe) | Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DIGICANN VENTURES | 0,004 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Digicann Ventures Inc. (DCNN) | le 30 septembre/September 2024
Trading in the shares of Digicann Ventures Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,003 | 0,00 % | CSE Bulletin: Reinstatement - WPD Pharmaceuticals Inc. (WBIO) | Toronto, Ontario--(Newsfile Corp. - le 20 décembre/December 2024) - Effective immediately, WPD Pharmaceuticals Inc. will be reinstated for trading. The Company has rectified the situation... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 33,930 | -0,73 % | IONIS PHARMACEUTICALS INC - 8-K, Current Report | ||
| SINOPHARM | 2,638 | +0,73 % | Lakeside enters into $1.5M sales deal with Sinopharm Hubei | ||
| INDIVA | 0,016 | 0,00 % | SNDL Inc.: SNDL Emerges as Canada's Leading Producer of Edibles with Indiva Acquisition | CALGARY, AB, Nov. 4, 2024 /CNW/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or the "Company") announced today that, in the context of Indiva Limited's ("Indiva" and together... ► Artikel lesen | |
| CSPC PHARMA | 0,600 | 0,00 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL | ||
| ORAMED PHARMACEUTICALS | 2,330 | +2,28 % | ORAMED PHARMACEUTICALS INC. - 8-K, Current Report | ||
| ADASTRA | 0,149 | -42,25 % | Adastra Holdings Ltd.: Adastra Holdings Announces Annual General Meeting | Langley, British Columbia--(Newsfile Corp. - December 10, 2024) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company"), a leader in cannabis processing and production, is pleased... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 16,125 | -0,37 % | Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview | SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
"The success of Acadia's two growing... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 0,875 | +0,81 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia | - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis - - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 288,80 | -2,40 % | Arrowhead Pharma und Madrigal gehen steil: Zwischen Adipositas- und Übernahmefantasie | Die Biotechnologie-Branche bietet viele spannende Storys. Einen aussichtsreichen Aktienkorb mit 14 verschiedenen Titeln bildet der Biotech Supertrends Index ab. Zuletzt sorgten im Index vor allem die... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,330 | -0,29 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc: Molecule amends, settles, converts debentures | ||
| NUMINUS WELLNESS | 0,024 | -15,73 % | Numinus Wellness Inc: Numinus Wellness closes sale of five Wellness Clinics | ||
| BAYER | 18,936 | +0,35 % | Bayer AG Aktie: Weitere Verluste erwartet | Die Bayer-Aktie verzeichnete am Handelstag einen deutlichen Rückgang und fiel im XETRA-Handel um 0,6 Prozent auf 19,64 Euro. Der Anteilsschein, der Anfang Januar noch bei 36,09 Euro notierte, entfernt... ► Artikel lesen |
Das Unternehmen RESPIRERX PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RESPIRERX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
